Drug or treatment

Relatlimab clinical trials

• 19Clinical trials
• 33Countries

Newest trials

All recruiting trials (19)

• Using ctDNA to decide whether to add ipilimumab for people on nivolumab and relatlimab

  This tests whether using a ctDNA blood test to guide adding ipilimumab for adults with advanced or metastatic melanoma on nivolumab and relatlimab leads to longer progression-free survival.

  Recruiting Phase 2 NYU Langone Health · New York, New York · NCT07504796

• HEPZATO KIT with Opdualag for metastatic melanoma that has spread to the liver

  This will try adding HEPZATO KIT to Opdualag (nivolumab + relatlimab) to see if it's safe and helps people with metastatic melanoma that has spread to the liver.

  Recruiting Phase 1/2 University of Wisconsin, Madison · Madison, Wisconsin · NCT07281924

• Comparing two immunotherapy combinations and their immune effects in unresectable or metastatic melanoma

  This will test whether two different first-line immunotherapy combinations produce different immune responses in tumors and blood of people with unresectable or metastatic melanoma.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07223411

• Neoadjuvant ipilimumab, relatlimab, and nivolumab combinations for resectable cutaneous and mucosal melanoma

  This phase 2 trial will test several immunotherapy combinations given before surgery to try to reduce recurrence in adults with resectable stage 3 cutaneous melanoma or resectable mucosal melanoma, including patients predicted or known to respond poorly to standard anti‑PD‑1 therapy.

  Recruiting Phase 2 Melanoma Institute Australia · Wollstonecraft, New South Wales · NCT06999980

• Sacituzumab govitecan with nivolumab, with or without relatlimab, for metastatic triple-negative breast cancer

  This trial tests whether adding nivolumab alone or nivolumab plus relatlimab to sacituzumab govitecan helps people with metastatic triple-negative breast cancer who have had one prior line of chemotherapy.

  Recruiting Phase 1/2 Yale University · New Haven, Connecticut · NCT06963905

• Nivolumab with or without relatlimab for newly diagnosed IDH‑wildtype glioblastoma

  This trial will test whether giving nivolumab alone or together with relatlimab around surgery helps adults with newly diagnosed IDH‑wildtype glioblastoma.

  Recruiting at 4 sites Phase 2 Duke University · New York, New York and 3 other locations · NCT06816927

• Relatlimab, nivolumab, and ipilimumab for melanoma that has spread to the brain

  This trial will test whether the combination of relatlimab, nivolumab, and ipilimumab can help adults with melanoma brain metastases, including those with and without symptoms.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT06712927

• Triplet combination of Relatlimab, Nivolumab, and Ipilimumab in first-line metastatic melanoma

  A first-line trial tests whether a three-drug combo can help people with metastatic melanoma, starting at a recommended dose.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT06683755

• Neoadjuvant Opdualag (nivolumab + relatlimab) versus nivolumab for resectable high-risk basal cell carcinoma

  This trial tests whether adding relatlimab to nivolumab before surgery helps people with resectable high‑risk basal cell carcinoma shrink tumors and improve surgical outcomes.

  Recruiting at 3 sites Phase 2 University of California, San Diego · Irvine, California and 2 other locations · NCT06624475

• Comparing two treatments for advanced non-small cell lung cancer

  This study is testing whether a combination of Nivolumab and Relatlimab with chemotherapy works better than Pembrolizumab with chemotherapy for people with advanced lung cancer.

  Recruiting at 239 sites Phase 3 Bristol-Myers Squibb · Mobile, Alabama and 329 other locations · NCT06561386

• Neoadjuvant therapy using Nivolumab and Relatlimab for skin cancer

  This study is testing a new combination of two immunotherapy drugs, Nivolumab and Relatlimab, to see if they can help people with advanced skin cancer do better before surgery.

  Recruiting Phase 2 Melanoma Institute Australia · Wollstonecraft, New South Wales · NCT06288191

• Combining two experimental drugs for advanced melanoma treatment

  This study is testing if a new combination of two experimental drugs can help people with advanced melanoma more than the current approved treatments.

  Recruiting at 92 sites Phase 3 Regeneron Pharmaceuticals · Chandler, Arizona and 112 other locations · NCT06246916

• Neoadjuvant immunotherapy for Merkel cell carcinoma

  This study is testing a combination of two immune treatments to see if they can help people with a type of skin cancer called Merkel cell carcinoma have better outcomes before surgery.

  Recruiting Phase 2 Melanoma Institute Australia · Wollstonecraft, New South Wales · NCT06151236

• Adding a new drug to immunotherapy for advanced nasopharyngeal cancer

  This study is testing if adding a new drug to standard immunotherapy can help people with advanced nasopharyngeal cancer live longer and feel better after their initial treatment.

  Recruiting at 83 sites Phase 2 National Cancer Institute (NCI) · Dublin, California and 94 other locations · NCT06029270

• Combining nivolumab and relatlimab for treating melanoma that has spread to the brain

  This study is testing if combining two drugs, nivolumab and relatlimab, can help people with melanoma that has spread to the brain feel better and improve their treatment outcomes.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05704647

• Using memory-like natural killer cells with nivolumab and relatlimab for advanced melanoma after previous treatments

  This study is testing if a new type of immune cell treatment combined with two existing drugs can help people with advanced melanoma who haven't improved with previous therapies.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT05629546

• Combining Sarilumab with Other Treatments for Advanced Melanoma

  This study is testing a new combination of treatments for people with advanced melanoma to see if it helps them feel better and live longer.

  Recruiting at 4 sites Phase 2 NYU Langone Health · Los Angeles, California and 3 other locations · NCT05428007

• Using Nivolumab to treat advanced skin cancer

  This study is testing if the drug Nivolumab, alone or with another drug called Relatlimab, can help people with advanced skin cancer feel better and improve their condition.

  Recruiting at 6 sites Phase 2 Salzburger Landeskliniken · Graz and 6 other locations · NCT04204837

• Nivolumab treatment for advanced basal cell carcinoma

  This study is testing if the drug nivolumab, alone or with other medications, can help people with advanced basal cell carcinoma that can't be removed by surgery.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT03521830

Quick answers

How many clinical trials of Relatlimab are recruiting right now?

19, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 33 countries. The most sites are in United States (15 trials), Australia (6 trials), Canada (3 trials), Austria (2 trials), Argentina (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 12, Phase 1/2: 3, Phase 3: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →